<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression
Mark M. Awad(Memorial Sloan Kettering Cancer Center), Lynette M. Sholl(Brigham and Women's Hospital), Priyanka Shivdasani(Brigham and Women's Hospital), Suzanne E. Dahlberg(Dana-Farber Cancer Institute), Geoffrey R. Oxnard(Foundation Medicine (United States)), Pasi A. Jänne(Harvard University), Daniel O. Savukoski(Brigham and Women's Hospital), Dimity Hall(Brigham and Women's Hospital), James G. Christensen, Jennifer Heng(Brigham and Women's Hospital), Peter S. Hammerman(Broad Institute), David M. Jackman(Brigham and Women's Hospital), Suman Verma(Brigham and Women's Hospital)
Cited by 687
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k